Treatment of Biochemical Recurrence of Gleason 9 Prostate Cancer
For Gleason 9 prostate cancer with biochemical recurrence after radical prostatectomy, you should offer salvage radiotherapy to the prostate bed combined with androgen deprivation therapy (ADT) for 6 months, particularly when PSA ≥0.7 ng/mL or PSA doubling time ≤6 months. 1
Risk Stratification and Treatment Decision Framework
Gleason 9 disease automatically places your patient in the high-risk biochemical recurrence category regardless of PSA kinetics. This designation is critical because it fundamentally changes the treatment approach from observation to aggressive intervention.
When to Initiate Salvage Therapy
Start salvage radiotherapy early when PSA is still low (ideally <0.5 ng/mL, but evidence supports benefit up to 2.0 ng/mL). 2, 3 The evidence consistently demonstrates that earlier intervention with salvage RT yields better outcomes than delayed treatment. Three major randomized trials (GETUG-AFU 16, RTOG 9601, and NRG/RTOG 0534 SPPORT) have established that patients with high-risk features—which includes Gleason Grade Group 4-5 (equivalent to Gleason 9)—derive significant benefit from adding ADT to salvage radiotherapy. 1
The Salvage RT + ADT Regimen
Radiation delivery: Target the prostate bed with external beam radiotherapy. The dose should be at least 64-66 Gy, though modern protocols often use 66-70 Gy based on dose-escalation data. 2, 3
ADT duration: Administer 6 months of ADT concurrently with and following salvage RT. 1 This is based on the GETUG-AFU 16 trial which specifically tested this duration in high-risk patients. While some older guidelines suggested 2-3 years of ADT for very high-risk disease, the contemporary evidence for biochemical recurrence specifically supports 6 months when combined with salvage RT.
ADT options: Use either:
- LHRH agonist (leuprolide, goserelin)
- LHRH antagonist (degarelix)
- Bilateral orchiectomy (rarely chosen but equally effective)
Alternative Approach: Intensified Systemic Therapy
If your patient has very high-risk features (PSA doubling time <6 months, persistently detectable post-operative PSA, or seminal vesicle involvement on original pathology), consider the EMBARK trial approach: enzalutamide 160 mg daily plus ADT instead of ADT alone. 4 This represents the most recent high-quality evidence (2024-2026) showing improved metastasis-free survival in high-risk biochemical recurrence. However, this is primarily indicated when:
- PSA doubling time is particularly short (<9 months)
- Patient is not a candidate for salvage RT
- There is concern about occult micrometastatic disease
When NOT to Use Salvage RT
Defer salvage RT if:
- PSMA-PET imaging demonstrates distant metastases (M1 disease)
- Multiple pelvic lymph nodes are positive on imaging (consider systemic therapy first)
- Patient has significant comorbidities limiting life expectancy to <5 years
In these scenarios, transition to systemic therapy with ADT plus a novel hormonal agent (abiraterone + prednisone, enzalutamide, or apalutamide) as per metastatic hormone-sensitive prostate cancer protocols. 5
Intermittent vs. Continuous ADT
Do not use intermittent ADT in the salvage setting for Gleason 9 disease. 6 While intermittent ADT is acceptable for lower-risk biochemical recurrence after radiotherapy, the high-grade nature of Gleason 9 disease and the salvage context warrant continuous therapy during the 6-month treatment window. The intermittent approach is specifically recommended for biochemical recurrence after primary radiotherapy, not after radical prostatectomy requiring salvage RT.
Imaging Before Treatment
Obtain PSMA-PET/CT imaging before initiating salvage therapy. 7, 8 This is now standard practice and will identify:
- Local recurrence in the prostate bed (confirms need for salvage RT)
- Pelvic lymph node involvement (may expand RT field)
- Distant metastases (changes treatment to systemic therapy)
If PSMA-PET is unavailable, conventional imaging (CT abdomen/pelvis and bone scan) is acceptable but less sensitive.
Critical Pitfalls to Avoid
Don't delay treatment waiting for PSA to rise further. The "wait and see" approach is outdated for Gleason 9 disease. Early intervention at lower PSA levels consistently shows better outcomes. 2, 1
Don't use ADT alone without salvage RT unless the patient has contraindications to radiation or imaging shows metastatic disease. ADT monotherapy for non-metastatic biochemical recurrence is inferior to combined modality treatment. 2
Don't omit ADT from the salvage RT regimen in Gleason 9 disease. The combination is superior to RT alone for high-grade disease, with Level I evidence supporting this approach. 1
Monitoring During and After Treatment
- Check PSA every 3 months for the first 2 years
- PSA nadir <0.2 ng/mL after salvage RT indicates good response
- Rising PSA despite salvage therapy indicates need for systemic therapy escalation
- Monitor for ADT side effects: hot flashes, sexual dysfunction, bone density loss, metabolic changes
If salvage RT + ADT fails (rising PSA after treatment), transition to continuous ADT with intensification using abiraterone + prednisone or enzalutamide, as these have proven survival benefits in the castration-sensitive setting. 5